Position in EXEL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$657,203
-$360,880 QoQ
Shares Held
15,323
-34.0% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Polymer Capital Management (US) LLC holds $8,321,577 across 23 Biotechnology names. EXEL ranks #6 (7.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
11,691 | $1,100,356 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,382 | $1,067,788 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
17,104 | $966,204 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,669 | $745,275 | |
| 5 | MRNA |
Moderna, Inc.
|
13,968 | $709,574 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
15,323 | $657,203 | |
| 7 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
7,339 | $615,888 | |
| 8 | DAWN |
Day One Biopharmaceuticals, Inc.
|
24,872 | $533,255 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $657,203 | 15,323 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,018,083 | 23,228 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $329,821 | 7,986 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $513,399 | 11,647 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $436,431 | 11,821 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||